Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events

References

• Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25–36.
   PubMed Web of Science ®Google Scholar
• Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76:17–28.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Rodríguez-Carrio J, Popa CD, et al. Cardiovascular effects of approved drugs for rheumatoid arthritis. Nat Rev Rheumatol. 2021;17:270–290.
   PubMed Web of Science ®Google Scholar
• Scott IC, Hider SL, Scott DL. Thromboembolism with Janus Kinase (JAK) inhibitors for rheumatoid arthritis: how real is the risk? Drug Saf. 2018;41:645–653.
   PubMed Web of Science ®Google Scholar
• Ketf C, Boutigny A, Mohamed N, et al. Risk of venous thromboembolism in rheumatoid arthritis. Joint Bone Spine. 2021;88(3):105122.
   PubMed Web of Science ®Google Scholar
• Ross R, Epstein FH. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115–126.
   PubMed Web of Science ®Google Scholar
• Tang Y, Liu W, Wang W, et al. Inhibition of JAK2 suppresses myelopoiesis and atherosclerosis in Apoe-/- mice. Cardiovasc Drugs Ther. 2020;34:145–152.
   PubMed Web of Science ®Google Scholar
• Yang X, Jia J, Yu Z, et al. Inhibition of JAK2/STAT3/SOCS3 signaling attenuates atherosclerosis in rabbit. BMC Cardiovasc Disord. 2020;20:133.
   PubMed Web of Science ®Google Scholar
• Gharavi NM, Alva JA, Mouillesseaux KP, et al. Role of the Jak/STAT pathway in the regulation of interleukin-8 transcription by oxidized phospholipids in vitro and in atherosclerosis in vivo. J Biol Chem. 2007;282:31460–31468.
   PubMed Web of Science ®Google Scholar
• Sperati CJ, Parekh RS, Berthier-Schaad Y, et al. Association of single-nucleotide polymorphisms in JAK3, STAT4, and STAT6 with new cardiovascular events in incident dialysis patients. Am J Kidney Dis. 2009;53:845–855.
   PubMed Web of Science ®Google Scholar
• García-Bermúdez M, López-Mejías R, Genre F, et al. Lack of association between JAK3 gene polymorphisms and cardiovascular disease in Spanish patients with rheumatoid arthritis. Biomed Res Int. 2015;2015:318364.
   PubMed Web of Science ®Google Scholar
• Yang X, Wan M, Cheng Z, et al. Tofacitinib inhibits ox-LDL-induced adhesion of THP-1 monocytes to endothelial cells. Artif Cells Nanomed Biotechnol. 2019;47:2775–2782.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang S, Wang Z, et al. Tofacitinib ameliorates atherosclerosis and reduces foam cell formation in apoE deficient mice. Biochem Biophys Res Commun. 2017;490:194–201.
   PubMed Web of Science ®Google Scholar
• Charles-Schoeman C, Burmester G, Nash P, et al. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2016;75:1293–1301.
   PubMed Web of Science ®Google Scholar
• Charles-Schoeman C, Wicker P, Gonzalez-Gay MD, et al. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Semin Arthritis Rheum. 2016;46:261–271.
   PubMed Web of Science ®Google Scholar
• Xie W, Huang Y, Xiao S, et al. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomized controlled trials. Ann Rheum Dis. 2019;78:1048–1054.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development program. RMD Open. 2020;6:e001395.
   PubMed Web of Science ®Google Scholar
• Charles-Schoeman C, DeMasi R, Valdez H, et al. Risk factors for major adverse cardiovascular events in phase III and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2019;71:1450–1459.
   PubMed Web of Science ®Google Scholar
• Cohen S, Curtis JR, DeMasi R, et al. Worldwide, 3-year, post-marketing surveillance experience with tofacitinib in rheumatoid arthritis. Rheumatol Ther. 2018;5:283–291.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Bingham CO, Cappelli LC, et al. Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based rheumatoid arthritis registry. ACR Open Rheumatol. 2021;3:173–184.
   PubMedGoogle Scholar
• Pfizer shares co-primary endpoint results from post-marketing required safety study of XELJANZ® (tofacitinib) in subjects with rheumatoid arthritis (RA). [cited 2022 Feb 3]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-co-primary-endpoint-results-post-marketing
   Google Scholar
• Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC). 2021 Jun 7-10. https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-7-10-june-2021
   Google Scholar
• Burmester GR, Curtis JR, Yun H, et al. An integrated analysis of the safety of tofacitinib in psoriatic arthritis across phase III and long-term extension studies with comparison to real-world observational data. Drug Saf. 2020;43:379–392.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Regueiro M, and Yun H, et al. Tofacitinib treatment safety in moderate to severe ulcerative colitis: comparison of observational population cohort data from the IBM MArketScan administrative claims database with tofacitinib trial data. Inflamm Bowel Dis. 2021;27(9):1394-1408.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Weinblatt ME, Burmester GR, et al. Cardiovascular safety during ttreatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol. 2019;71:1042–1055.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Genovese MC, Takeuchi T, et al. Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheumatol. 2019;46:7–18.
   PubMed Web of Science ®Google Scholar
• Bieber T, Thyssen JP, Reich K, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venerol. 2021;35:476–485.
   PubMed Web of Science ®Google Scholar
• Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheumat Dis. 2021;80:304–311.
   PubMed Web of Science ®Google Scholar
• Conaghan PG, Mysler E, Tanaka Y, et al. Upadacitinib in rheumatoid arthritis: a benefit-risk assessment across a phase III program. Drug Saf. 2021;44:515–530.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Anderson JK, Magrey M, et al. Trial of upadacitinib and Adalimumab for psoriatic arthritis. N Engl J Med. 2021;384:1227–1239.
   PubMed Web of Science ®Google Scholar
• Rubbert-Roth A, Enejosa J, Pangan AL, et al. Trial of upadacitinib or Abatacept in rheumatoid arthritis. N Engl J Med. 2020;383:1511–1521.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kalunian K, Gottenberg JE, et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA. 2019;322:315–325.
   PubMed Web of Science ®Google Scholar
• Combe B, Kivitz A, Tanaka Y, et al. Filgotinib versus placebo or Adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomized clinical trial. Ann Rheum Dis. 2021;80:848–858.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Westhovens RR, and Winthrop KL, et al. Safety and efficacy of filgotinib: up to 4-year results from an open-label extension studt of phase II rheumatoid arthritis programs. J Rheumatol. 2021;48(8):1230-1238.
   Web of Science ®Google Scholar
• Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76:1253–1262.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Increased risk of blood clots in lungs and death with higher dose of xeljanz (tofacitinib) for rheumatoid arthritis, https://www.ema.europa.eu/en/news/increasedrisk-blood-clots-lungs-death-higher-dose-xeljanztofacitinib-rheumatoid-arthritis. 2019.
   Google Scholar
• Xie W, Xiao S, Huang Y, et al. Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials. Ther Adv Musculoskelet Dis. 2019;11:1759720X19895492.
   PubMed Web of Science ®Google Scholar
• Desai RJ, Pawar A, Weinblatt ME, et al. Comparative risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors: a cohort study of rheumatoid arthritis patients. Arthritis Rheumatol. 2019;71:892–900.
   PubMed Web of Science ®Google Scholar
• Kim SC, Schneeweiss S, Liu J, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res. 2013;65:1600–1607.
   PubMed Web of Science ®Google Scholar
• Mease P, Charles-Schoeman C, Cohen S, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheumat Dis. 2020;79:1400–1413.
   PubMed Web of Science ®Google Scholar
• Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology. 2019;58:i34–i42.
   PubMed Web of Science ®Google Scholar
• Kremer J, Huizinga TWJ, Chen L, et al. Analysis of neutrophils, lymphocytes, and platelets in pooled phase 2 and phase 3 studies of baricitinib for rheumatoid arthritis (FRI0090). Ann Rheum Dis. 2017;76:512.
   Web of Science ®Google Scholar
• Genovese MC, Smolen JS, Takeuchi T, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 5.5 years: an updated integrated safety analysis (Abstract #511). Arthritis Rheumatol. 2017;69:Abstract 511.
   Web of Science ®Google Scholar
• Mease PJ, Kremer J, Cohen S, et al. Thromboembolic events in the tofacitinib rheumatoid arthritis, psoriasis, psoriatic arthritis and ulcerative colitis development programs (Abstract 16L). Arthritis Rheumatol. 2017;69:Abstract 16L.
   Google Scholar
• Ungprasert P, Srivali N, Spanuchart I, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2014;33:297–304.
   PubMed Web of Science ®Google Scholar
• Ho Lee Y, and Song GG. Impact of Janus kinase inhibitors on the risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 2020;79(10):e122.
   Google Scholar
• Yates M, Mootoo A, Adas M, et al. Venous thromboembolism risk with JAK inhibitors: a meta-analysis. Arthritis Rheumatol. 2021;73:779–788.
   PubMed Web of Science ®Google Scholar
• Winthrop K, Tanaka Y, and Takeuchi T, et al. Integrated safety of filgotinib in patients with moderately or severely active rheumatoid arthritis receiving treatment for up to 5.5 years [abstract]. Arthritis Rheumatol. 2022;81(2):184–192.
   Google Scholar
• Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685–699.
   PubMed Web of Science ®Google Scholar